Selecting the Best Prostate Cancer Surgeons and Hospitals in India for Australian Patients

Author:- Dr. Dheeraj Bojwani Date Created:- 23-08-2026

Most Australians should never need this guide, and I want to say that plainly before anything else. Australian urology is genuinely excellent, close to free at the point of use through Medicare, and moving primary treatment overseas is rarely the right answer. This guide exists for a narrower group — and it is worth being precise about who that is before a single criterion is discussed. In 24 years of guiding international patients into Indian hospitals, I have turned away more Australians with prostate cancer than from almost any other diagnosis, precisely because so many are genuinely well served by active surveillance rather than surgery at all. If none of the four reasons above describes your situation, the right next step is a direct conversation with your Australian urologist about surveillance, not this document.

Healing Journeys of Australian Patients

Australian Patients Share Their Experience

Key Takeaways

• The guide begins with an important caution: not every Australian patient with prostate cancer needs surgery. Active surveillance may be appropriate for some low- and intermediate-risk cases, so patients should first discuss surveillance and treatment choices with their Australian urologist.
• Before seeking an overseas opinion, patients should have a confirmed Gleason grade, PSA history and appropriate imaging, including PSMA PET/CT where relevant. The guide recommends taking the actual biopsy pathology, PSA history and the Australian urologist's written recommendation to the overseas consultation.
• The surgeon and team account for 55 out of 100 points, with nerve-sparing technique and the surgeon's personal trifecta rate receiving the highest individual weight of 15 points. Radical prostatectomy volume, honest discussion of active surveillance, approach selection and personal surgical involvement are also heavily weighted.
• The illustrative trifecta chart shows a major difference between lower- and higher-volume surgeons, with roughly 38% versus 72% trifecta rate. The guide stresses that patients should ask for the surgeon's own trifecta rate rather than relying on robotic-platform marketing or general hospital claims.
• Hospital assessment accounts for 45 out of 100 points and includes genuine PSMA PET/CT availability, multidisciplinary urology tumour-board review, continence and potency rehabilitation, verifiable accreditation and complete records for the Australian urologist.
• The guide identifies four warning signs: surgery recommended without genuine active-surveillance discussion, pricing before pathology review, vague trifecta results and unsupported cure claims. It also recommends involving the Australian urologist early and arranging PSA follow-up before leaving Australia.

Quick Facts

Treatment

Prostate Cancer Surgery

Country

India

Patients

Australian Patients

Main Procedure

Radical Prostatectomy

Key Alternative

Active Surveillance

Key Technique

Nerve-Sparing Surgery

Selection Criteria

10 Weighted Criteria

Surgeon & Team Weight

55 out of 100

Hospital Weight

45 out of 100

Key Specialist

Urologist / Urologic Oncologist

Highest Criterion

Personal Trifecta Rate

Key Experience

Radical Prostatectomy Volume

Key Imaging

PSMA PET/CT

Team Approach

Multidisciplinary Urology Tumour Board

Rehabilitation

Continence & Potency Programme

Hospital Requirement

Verifiable Accreditation

Warning Signs

No Surveillance Discussion or Vague Outcomes

Follow-Up

Australian Urologist

Required Records

Operative Note, Final Pathology & PSA Plan

Author

Dr. Dheeraj Bojwani

Experience

24+ Years

In Brief

For Australian patients considering prostate cancer surgery in India, the guide recommends first confirming the diagnosis and discussing whether active surveillance is genuinely appropriate. Patients should then evaluate the surgeon's personal trifecta rate, radical prostatectomy volume, nerve-sparing experience and approach selection. The hospital should provide appropriate PSMA PET/CT staging, multidisciplinary tumour-board review and structured continence and potency rehabilitation. Patients should obtain the final pathology with margin status, full operative records and a specific PSA surveillance schedule. Follow-up should be arranged with the Australian urologist before travelling.

Before you choose anyone: get the diagnosis pinned down at home

Every criterion below depends on one thing being settled first: a confirmed Gleason grade, PSA trend over time, and full imaging including PSMA PET/CT where appropriate, obtained in Australia, where Medicare pays for it. A surgeon anywhere in the world can only be as good as the diagnosis he or she is working from.

Get your biopsy pathology, PSA history, and a written note on what your Australian urologist recommended and why — including whether active surveillance was genuinely discussed — before your first overseas conversation. This matters because the decision between surveillance and treatment is a real clinical judgement for many low- and intermediate-risk cases, not a fixed fact.

Part one: judging the surgeon and the urology team

1. Nerve-sparing technique and the surgeon's personal trifecta rate. This is the single heaviest criterion in this guide, and deliberately so. The trifecta — cancer control, continence and erectile function preserved together — is what actually determines your quality of life afterward, and it depends heavily on the individual surgeon, not the robotic platform's marketing.

2. Volume in radical prostatectomy specifically. Not general urology, not urologic oncology broadly — the number of prostatectomies performed last year. Ask for the figure in writing, robotic and open combined and separately.

3. Active surveillance discussed honestly, not skipped past. A genuine specialist will tell you plainly if your disease is low-risk enough to monitor rather than treat, and will explain the structured surveillance protocol involved, not simply move straight to a surgical recommendation.

4. Robotic versus open judgement, not a default. Both approaches can achieve excellent trifecta outcomes in experienced hands. Ask why a specific approach is being recommended for your anatomy and disease, not because it is the only one the surgeon or hospital offers.

5. Personally operates, and speaks to you first. Insist on a video consultation with the surgeon who will actually operate, not a coordinator, before any deposit moves.

Part two: judging the hospital

6. PSMA PET/CT genuinely available, not an exception-only pathway. This imaging has become the international standard for accurately staging high-risk disease and detecting recurrence. Ask whether it will be used as standard for your case, not as a special request.

7. A multidisciplinary urology tumour board. Ask whether your case will be reviewed by a genuine team, including urology, radiation oncology and radiology, not decided by one surgeon alone.

8. A structured continence and potency rehabilitation programme. Ask what specific rehabilitation support, pelvic floor physiotherapy and follow-up is built into your care after surgery, not left to arrange yourself.

9. Accreditation you can verify yourself. JCI is the international arm of the body accrediting hospitals across the United States; NABH is India's national equivalent, recognised by the same global standards authority.

10. A record your Australian urologist can use. Before you leave you should hold the full operative note, final pathology with margin status, and a specific PSA surveillance schedule.

What the quote should say, and what it usually omits

In 24 years I have found that disputes almost never concern the quoted price. They concern what the quote silently omitted.

Insist on a written, itemised figure that states what happens if intraoperative findings change the plan, and what that would cost. Ask whether PSMA PET/CT and any nerve-monitoring technology are included or billed separately. Understand what does not travel with you: Medicare pays nothing for treatment overseas, your health fund rebate applies to Australian admissions, and standard travel insurance excludes planned surgery and its complications. Pay a deposit to secure the date, never the full balance in advance.

Four Signals that Should Make You Pause

1. Surgery recommended without a genuine discussion of active surveillance. Not every prostate cancer needs immediate treatment, and a unit that skips this conversation is telling you something about how it operates.

2. A price quoted before your pathology has been reviewed. Nobody can price prostate cancer surgery without having seen your biopsy and imaging.

3. Vagueness about the surgeon's own trifecta rate. This is the number that determines your quality of life afterward, and a confident surgeon gives it immediately.

4. Any claim of a cure your Australian urologist has not heard of. Legitimate prostate cancer surgery has no need to oversell itself.

Australia-specific considerations most patients miss

Tell your Australian urologist early, not after the fact. Most are more sympathetic to a second opinion than patients expect, and a urologist informed from the outset is better placed to manage your PSA surveillance afterward.

Arrange your ongoing follow-up before you leave. Confirm your Australian urologist is willing to take over PSA monitoring based on overseas surgical findings, and give them the dates in advance.

Send the tissue, not just the report. A pathology re-read or second opinion requires the actual biopsy slides, not a typed summary.

Ask about the Medical Treatment Overseas Program. Where a specific technique is genuinely unavailable in Australia, this Commonwealth programme can in some circumstances fund treatment abroad.

Apply for both visas together. Australian passport holders are eligible for India's electronic medical visa, with an e-medical attendant visa for whoever travels with you.

Ask what happens if the diagnosis changes intraoperatively. Establish the plan before you travel, and ask an Australian urologist the parallel question directly.

The Questions, in the Order You Should Ask Them

A closing word

Prostate cancer surgery rewards precision more than almost any decision in this series, because the trifecta of cancer control, continence and potency shapes decades of life afterward, and because for many patients the right answer is not surgery at all. If your situation is a second opinion, nerve-sparing surgery, a faster private option or a rare presentation — confirm active surveillance was genuinely considered, weight trifecta rate as heavily as volume, and ask directly for the surgeon's own numbers. If you would like a second opinion on your pathology and imaging, send it and I will look at it properly — including telling you that surveillance, not surgery anywhere, is the right answer for your case, which for prostate cancer is an answer I give often.

Frequently Asked Questions by Australians about Prostate Cancer Surgeons and Hospitals in India

Does every prostate cancer patient need surgery?

No. The guide specifically emphasises that some low- and intermediate-risk patients may be better suited to active surveillance rather than immediate treatment.

What should patients confirm before seeking an overseas opinion?

They should have their Gleason grade, PSA history, biopsy pathology and appropriate imaging available, including PSMA PET/CT where relevant.

What is the trifecta rate?

The trifecta combines cancer control, urinary continence and preservation of erectile function. The guide treats the surgeon's personal trifecta rate as the most important individual selection criterion.

How should patients assess prostatectomy experience?

Patients should ask how many radical prostatectomies the surgeon performed in the previous year, with robotic and open cases reported separately as well as combined.

Why is active surveillance discussion important?

A genuine specialist should explain whether the patient's disease can safely be monitored instead of automatically recommending surgery.

Should surgery always be robotic?

No. The guide states that both robotic and open approaches can achieve good outcomes in experienced hands. The choice should be based on the patient's anatomy and disease rather than being an automatic hospital preference.

Why is PSMA PET/CT important?

The guide highlights PSMA PET/CT as important for staging high-risk disease and detecting recurrence, and recommends asking whether it is genuinely available for the patient's case.

What rehabilitation should the hospital provide?

Patients should ask about a structured programme covering continence, potency, pelvic-floor physiotherapy and follow-up, rather than arranging these services independently.

What warning signs should make patients pause?

The guide identifies lack of active-surveillance discussion, pricing before pathology review, vague personal trifecta results and unsupported cure claims as important warning signs.

What should Australian patients take home after surgery?

They should obtain the complete operative note, final pathology including margin status and a specific PSA surveillance schedule for their Australian urologist.

Sources

• Published urologic oncology literature on radical prostatectomy learning curves and trifecta outcomes — pubmed.ncbi.nlm.nih.gov
• National Medical Commission, recognised postgraduate medical qualifications in urology — nmc.org.in
• Australian Government Medical Treatment Overseas Program, eligibility criteria — health.gov.au
• Joint Commission International, accreditation registers — jointcommissioninternational.org
• National Accreditation Board for Hospitals & Healthcare Providers, accreditation registers — nabh.co
• High Commission of India, e-Visa categories and eligibility — indianvisaonline.gov.in

Page Summary

This seven-page guide helps Australian patients assess whether prostate cancer surgery in India is appropriate and, if so, how to evaluate surgeons and hospitals. It strongly foregrounds active surveillance as a legitimate option for selected patients and recommends confirming the diagnosis in Australia before considering overseas treatment. The guide uses 10 weighted criteria, with 55 points for the surgeon and team and 45 for the hospital. Key factors include nerve-sparing expertise, personal trifecta rate, radical prostatectomy volume, treatment judgement, PSMA PET/CT, tumour-board review and rehabilitation.

Citation Block

Field	Information
Topic	Prostate Cancer Surgeons & Hospitals
Treatment	Prostate Cancer Surgery
Country	India
Patients	Australian Patients
Main Procedure	Radical Prostatectomy
Key Alternative	Active Surveillance
Key Technique	Nerve-Sparing Surgery
Key Specialist	Urologist / Urologic Oncologist
Selection Criteria	10 Weighted Criteria
Surgeon & Team Weight	55 out of 100
Hospital Weight	45 out of 100
Highest Criterion	Personal Trifecta Rate
Key Experience	Radical Prostatectomy Volume
Key Imaging	PSMA PET/CT
Team Approach	Multidisciplinary Urology Tumour Board
Rehabilitation	Continence & Potency Programme
Hospital Requirement	Verifiable Accreditation
Warning Signs	No Surveillance Discussion or Vague Outcomes
Follow-Up	Australian Urologist
Required Records	Operative Note, Final Pathology & PSA Plan